Manufacturing Cellares and Papillon partner for PPL-001 manufacturing automation Pharmaceutical Business ReviewPPL-001 is a gene-corrected haematopoietic stem and progenitor cell (HSPC) therapy.Read full story pharminent July 22, 2026 (Last updated: July 27, 2026) Pharmaceutical Business Review PPL-001 is a gene-corrected haematopoietic stem and progenitor cell (HSPC) therapy. Read full story Post navigation Previous: Novo Nordisk Sues Eli Lilly Over ‘Deceptive’ GLP-1 AdvertisingNext: US generic tariff reprieve on the rocks as Trump proposes 100% rate in 2028 Related Stories Manufacturing BMS banks on Texas for $2.3bn multi-modal manufacturing facility pharminent August 11, 2026 Manufacturing AsymBio to secure $184m to support growth in biologics manufacturing pharminent August 5, 2026 Manufacturing Lilly and Resilience invest $750M in diabetes and obesity drug device supply pharminent July 31, 2026
